Double-blind evaluation of etodolac (200 mg, 400 mg) compared with zomepirac (100 mg) and placebo on third molar extraction pain.
This controlled, single dose study has demonstrated that compared with placebo, substantial analgesia is obtained with 200 and 400 mg doses of etodolac. The analgesic effects of both doses of etodolac were not notably different from each other or significantly different from zomepirac, a proven analgesic. With respect to safety, both doses of etodolac were well tolerated, with no reports of serious or dose related adverse side effects.
D000085:Acetates / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D017308:Etodolac; D006801:Humans; D008875:Middle Aged; D008964:Molar, Third / Q000601:surgery; D010147:Pain Measurement; D010149:Postoperative Pain / Q000209:etiology / Q000517:prevention & control*; D011758:Pyrroles / Q000627:therapeutic use*; D011897:Random Allocation; D014046:Tolmetin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014081:Tooth Extraction / Q000009:adverse effects
D000085:Acetates; D000894:Anti-Inflammatory Agents, Non-Steroidal; D011758:Pyrroles; D017308:Etodolac; C020549:zomepirac; D014046:Tolmetin